VIVAMEDA LTD

FOUNDER AND OPERATOR

Founder Portfolio

OLIVER NOLD

The operator behind the panel.
A decade of owned companies, then one instrument.

BEFORE VIVAMEDA

10+	**4**	**5**	**25**
years owning and operating companies	businesses built and exited	research studies published in 2026	engagements delivered Feb to Aug 2026

Founder, Vivameda Ltd · Longitudinal data · Commercial intelligence
Vivameda Ltd, Cyprus · Prepared August 2026

VMD.21962.150826.301

01 / THE OPERATOR

The operator behind the panel

Oliver Nold builds and runs Vivameda, a commercial intelligence company built on a proprietary longitudinal workforce panel. He designed the commercial architecture on top of it and delivers the work himself.

The premise is narrow and it holds across every engagement. Financial statements, market reports and current-state databases all describe a single moment. None of them says how an organisation arrived there, which is the part that predicts what it does next. Workforce structure does, it is observable at company level, and it survives for companies that no longer exist.

He arrived at that through a decade of owning companies rather than advising them. Cloud software built and sold, consumer commerce scaled to seven figures and exited, a technology platform co-founded and later sold, and a consulting and AI umbrella eventually merged into Vivameda. Each phase added a layer: first how populations behave, then how markets signal, then the infrastructure that produces and structures the signal itself.

What that history contributes is not technique. It is the ability to read a commercial situation from the inside, because the risk always sat with him rather than with a client, and to move from a question to a delivered artifact in days rather than quarters.

4M+	48M	1.88B	2
companies in the panel 100+ countries	observed company-year records, 1950 to 2026	skill rows 46.5M capability buckets	data layers, reported separately, never netted

THE CONNECTING THREAD

Every capability in this document was built inside a company under real commercial risk. The research discipline is not academic in origin. It exists because a technical buyer finds the weak claim first, and the only durable answer is to have removed it before he arrives.

What Vivameda is, in one page

A research instrument with a concierge delivery model on top of it. Not a database, not a lead list, and not a monitoring dashboard.

The asset

For every company and every year, the panel carries an observed workforce size, a role composition and a capability composition, all on one taxonomy. That single point is what makes it an instrument rather than a store of records: a company of 2013 is directly comparable with another of 2016, and a company that no longer exists is comparable with one that does.

What it is used to decide

Which companies are structurally ready to scale before the growth curve is visible. Which are structurally exposed before a market removes them. Whether a stated capability appears anywhere in the workforce. What an organisation already was, decades before the question mattered. And what a company was made of in the years before it emptied.

Who it is for

Private equity and venture funds sourcing and monitoring. Acquirers running diligence on capability rather than accounts. Alternative data buyers and quantitative funds. Teams needing structured ground truth for model training. Executive search, corporate finance and advisory practices building a defensible pipeline.

> THE RULES THAT DO NOT MOVE
>
> Classification rules are fixed in writing before any outcome is examined, and are disclosed on request. The historical and current layers are reported separately and never arithmetically spliced, because their observation depth differs by orders of magnitude. Panel figures are observed workforce records on a uniform taxonomy, not reported corporate headcount. Indicators that fail are published with their coefficients rather than quietly dropped.

WHERE THIS IS EVIDENCED

Vivameda Research Portfolio 2026 · five studies testing what the instrument can establish and where it stops

Vivameda Case Study Book · twenty engagements applying it to real economic decisions

03 / WHAT CAME BEFORE

A decade of owned companies

Every business below was owned or co-owned and built hands-on, in several cases to an exit. None of it was learned from an advisory seat. Each entry states what it contributed to the instrument that came after.

2015 TO 2017 · CLOUD SOFTWARE

Building and pricing software

Cloud-based applications and infrastructure designed, built and taken to market on subscription pricing, with business development and early customer acquisition handled directly.

Contributed: how software is made, priced and sold, learned before any of the data work started.

2015 TO 2019 · EXITED

Growth and community agency

Acquisition systems and community-led distribution for early-stage startups and digital businesses, alongside its own educational products. Operated in parallel with the software ventures and exited after several years.

Contributed: a first read on how populations behave at scale, and the instinct that behaviour leaves a structural trace.

2017 TO 2019 · INFRASTRUCTURE

Measurement and attribution practice

Performance measurement and automation for software and digital companies: tracking, attribution and the systems that make a result repeatable rather than one-off.

Contributed: the habit of building the measurement layer before trusting the number. This is where execution became infrastructure.

2018 TO 2021 · SOLD

Technology platform

A technology platform serving remote professionals, co-founded with the growth and marketing function owned end to end. The company was later sold.

Contributed: marketplace mechanics under real supply constraints, and what it takes to scale a platform across borders.

From operating to instrument

2020 TO 2023 · SEVERAL EXITS

Consumer commerce and venture building

Several consumer commerce businesses built, scaled and exited across German-speaking and international markets. The largest reached seven-figure revenue before exit. A second was built from scratch, expanded into international markets and later sold.

Contributed: direct commercial risk and cashflow discipline at velocity. Reading market signal became instinct here rather than analysis.

2020 TO 2025 · MERGED INTO VIVAMEDA

North Resolutions

An umbrella for consulting, software, automation and AI work serving international clients, which also built its own software and models. The assets that became Vivameda originated here.

Contributed: the turn from acting on data to building the systems that produce and structure it. Automation, entity resolution and AI-supported development.

2021 TO 2025 · ADVISORY

Commercial strategy and deal development

Helping founder-led companies sharpen positioning, build traction and prepare for conversations with investors, partners and strategic buyers, including target identification.

Contributed: how a company is assessed from the outside, which is precisely the question the panel now answers with evidence instead of narrative.

2025 TO PRESENT · CURRENT COMPANY

Vivameda

North Resolutions was merged into Vivameda and the focus narrowed to one asset: a longitudinal workforce and capability panel, the research that validates it, and the concierge delivery model that puts it in front of funds, acquirers and advisory firms.

Ten years of commercial work resolving into a single question: what does the composition of a workforce reveal about what an organisation is capable of becoming, and how early.

04 / TRACK RECORD

Selected record

Verifiable entries only. Each is either a company that was built and sold, a document that exists, or an agreement that was executed.

01	Founded Vivameda and built the commercial architecture on a proprietary longitudinal workforce panel covering more than four million companies across more than one hundred countries.
02	Published five research studies on the panel in 2026, each with pre-registered classification, held-out or permutation validation, and a disclosed scope section.
03	Delivered twenty five client, prospect and counterparty engagements between February and August 2026 across private equity, venture, alternative data, executive search, compliance software and advisory.
04	Scaled a German-language consumer commerce business to seven-figure revenue before exit.
05	Built and exited a growth and community agency serving early-stage startups and digital businesses.
06	Co-founded and helped scale a technology platform serving remote professionals, later sold.
07	Built and sold a consumer store created from scratch and expanded into international markets.
08	Built and shipped cloud-based software products from concept through to subscription revenue.
09	Built North Resolutions as a multi-year consulting, software and AI umbrella, later merged into Vivameda.
10	Negotiated and closed licensing, partnership and investment terms for Vivameda, including an exclusivity and revenue-share agreement with an integration partner.

Where the work actually sits

Three domains, built in sequence and now converging on one instrument. The order matters: the data architecture came before the research discipline, and the research discipline came before the commercial argument it now supports.

DATA AND PANEL ARCHITECTURE

Longitudinal panel design · Entity resolution · Cohort construction · Capability taxonomies · Two-layer data architecture · Provenance and licensing documentation

RESEARCH AND ANALYSIS

Pre-registered study design · Held-out and permutation validation · Signal validation and signal killing · Null-result reporting · Scope and limitation framing · Diligence and portfolio analysis

COMMERCIAL EXECUTION

Defining a universe from structure · Concierge intelligence delivery · Engagement design · Partner and licensing structures · Investor positioning · Founder-led sales

> **WHY THE SEQUENCE MATTERS**
>
> An operator who has only carried commercial risk builds a persuasive artifact. An analyst who has only carried research discipline builds an unusable one. The panel exists because both constraints were present at the same time, and the documents it produces are written to survive a technical reader who is looking for the weakest claim.

06 / EXTERNAL VALIDATION

In their words

Written by a client and a counterparty on their own initiative, both in August 2026. Statements about earlier businesses are held in those companies' own records and are not reproduced here, because they describe work that predates the instrument.

> *Most data providers tell you what a company is today. Vivameda tells you how it became that, over decades, cleanly and verifiably, including companies that stopped existing long ago.*
>
> *What convinces me: Oli Nold proves rather than asserts. His studies name their limits first and hold up under technical review. For anyone working with timing and target selection, that is a different category. I build on it myself.*
>
> ALFRED ROSSI, CLIENT · SWISS AI PIONEER SINCE 1982 · AUGUST 2026 · TRANSLATED FROM GERMAN

> *Oli has a habit that is rarer than it sounds: he sees where a market is going before there is a market. With Vivameda he built a longitudinal company and workforce dataset, decades of ground truth on how companies actually evolve, at a point when most people still assumed the open web was enough to train AI on. It wasn't, and now everyone knows it. He knew earlier.*
>
> *What I appreciate about working with him is that the foresight comes with delivery attached. He has built and sold businesses before, and it shows in how quickly he moves from idea to something you can actually use.*
>
> MARTINA MEYER, PRODUCT BUILDER AND PARTNER AT SINNHAFT · AUGUST 2026

How the work is taken on

Founder-led and concierge. Engagements start narrow, on one defined economic decision, with a sample the buyer can challenge before anything is scaled. The analysis is built and interpreted rather than handed over as a feed.

Narrow question first

The first conversation establishes one decision that a better piece of evidence would improve, and the universe that decision applies to. Everything else follows from those two things. A brief that begins with a data requirement rather than a decision produces a file nobody acts on.

Sample before scale

A first engagement returns a sample built against the buyer's own universe, sized so that every claim in it can be checked. What comes back is either a labelled feature file, one row per company with measured fields, flags and explanation columns, or a written analysis in the form of the published studies.

Delivered personally

Vivameda operates lean and remote from Cyprus. The research, the analysis and the client work are delivered by the founder rather than routed through a delivery team, which is what makes the turnaround measured in days and what keeps the constraint stated before the buyer finds it.

The constraint stated first

Coverage, observation density and the boundary between the two data layers are set out before a figure is presented rather than after it is questioned. Technical buyers read the limitations section first, and stating the tradeoff openly is consistently the passage that earns the engagement rather than the one that loses it.

> WHAT THE ENGAGEMENT MECHANICS LOOK LIKE
>
> How a sample becomes a recurring feed, how the contact layer is released, and how signals are revalidated against a client's own closed and lost record are set out in the Case Study Book, which is where that argument is carried by evidence rather than described.

Short biography

Oliver Nold is a Swiss-born entrepreneur who has built and operated companies internationally for over a decade. He runs Vivameda, a commercial intelligence company built on a proprietary longitudinal workforce panel, and delivers its research and client work himself.

Before Vivameda he built, scaled and exited companies in cloud software, consumer commerce and platform businesses, and ran a consulting and AI umbrella whose assets became the current company. He has operated remote-first across Switzerland, the United Kingdom, the United States, Portugal, Indonesia, Spain and Cyprus, and works in English and German.

COMPANY	Vivameda Ltd, Cyprus
EMAIL	oli@vivameda.com
WEBSITE	vivameda.com
LINKEDIN	linkedin.com/in/oli-nold
LANGUAGES	English, German

> **THE BEST FIRST STEP**
>
> A defined universe and one economic decision. A company list, a market definition, a portfolio or an acquisition universe, and the question it is meant to answer. What comes back is a sample built against that universe, which is the only useful basis for deciding whether the instrument is worth more than a conversation.

COMPANION DOCUMENTS

Vivameda Research Portfolio 2026 · Five studies, one panel. What the instrument establishes, and where it stops.

Vivameda Case Study Book · Twenty engagements. What happens when the instrument meets real decisions.